NeuraLieve Garners $3,900,000 New Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=b7eb7f0c-96af-4040-bb42-3fb65ef28b10&Preview=1 -
Date
1/11/2010 -
Company Name
NeuraLieve -
Mailing Address
240 N. Wolfe Rd. Sunnyvale, CA 94085 -
Company Description
Neuralieve is a medical technology company that is pursuing a completely new approach to
the treatment of migraine headache. Our core technology is based on the science of transcranial magnetic stimulation (TMS), a modality that has been used extensively in brain research. In studying TMS for the treatment of headache, we believe we are breaking new ground in non-drug, non-behavioral therapy for migraine. We think that TMS has the potential to become a highly effective option for patients who need relief beyond that provided by today’s widely used pharmacologic agents and to offer patients a safe, effective alternative to existing drug therapy. -
Website
http://www.neuralieve.com -
Transaction Type
Venture Equity -
Transaction Amount
$3,900,000 -
Transaction Round
Undisclosed -
Proceeds Purposes
Proceeds purposes were not disclosed. -
M&A Terms
-
Venture Investor
Undisclosed
